1. Sabouret P. et al. REACH: international prospective observational registry in patients at risk of atherothrombotic events. Results for the French arm at baseline and one year // Archives of cardiovascular diseases. - 2008. - Т. 101, № 2. - С. 81-88.
2. Twine C. P. et al. Editor’s Choice - European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases // European journal of vascular and endovascular surgery. - 2023. - Т. 65, № 5. - С. 627-689.
3. Бокерия Л. А. и др. Национальные рекомендации по диагностике и лечению заболеваний артерий нижних конечностей. - Москва, 2019.
4. Fowkes F. G. R. et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial // JAMA. - 2010. - Т. 303, № 9. - С. 841-848.
5. Belch J. et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease // BMJ. - 2008. - Т. 337. - С. 1840.
6. Ambler G. K. et al. Umbrella review and metaanalysis of antiplatelet therapy for peripheral artery disease // Journal of British Surgery. - 2020. - Т. 107, № 1. - С. 20-32.
7. CAPRIE Steering Committee et al. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) // The Lancet. - 1996. - Т. 348, № 9038. - С. 1329-1339.
8. Baigent C. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials // Lancet. - 2009. - Т. 373, № 9678. - С. 1849-1860.
9. Mahmoud A. N. et al. Efficacy and safety of aspirin in patients with peripheral vascular disease: an updated systematic review and metaanalysis of randomized controlled trials // PLoS one. - 2017. - Т. 12, № 4. - С. e0175283.
10. Qian J., Yang X. H. A metaanalysis of randomized controlled trials on antiplatelet agents versus placebo/control for treating peripheral artery disease // Medicine. - 2015. - Т. 94, № 31. - С. e1293.
11. De Carlo M. et al. Efficacy and safety of antiplatelet therapies in symptomatic peripheral artery disease: a systematic review and network metaanalysis // Current Vascular Pharmacology. - 2021. - Т. 19, № 5. - С. 542-555.
12. Hiatt W. R. et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease // New England Journal of Medicine. - 2017. - Т. 376, № 1. - С. 32-40.
13. Bhatt D. L. et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial // Journal of the American College of Cardiology. - 2007. - Т. 49, № 19. - С. 1982-1988.
14. Fanari Z. et al. Longterm use of dual antiplatelet therapy for the secondary prevention of atherothrombotic events: metaanalysis of randomized controlled trials // Cardiovascular Revascularization Medicine. - 2017. - Т. 18, № 1. - С. 10-15.
15. De Schryver E., Algra A., van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease // Cochrane Database of Systematic Reviews. - 2006. - № 2.
16. Cosmi B., Conti E., Coccheri S. Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication // Cochrane Database of Systematic Reviews. - 2014. - № 5.
17. Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease // New England Journal of Medicine. - 2007. - Т. 357, № 3. - С. 217-227.
18. Eikelboom J. W. et al. Rivaroxaban with or without aspirin in stable cardiovascular disease // New England Journal of Medicine. - 2017. - Т. 377, № 14. - С. 1319-1330.
19. Kreutzburg T. et al. Editor’s Choice - The GermanVasc score: a pragmatic risk score predicts five year amputation free survival in patients with peripheral arterial occlusive disease // European Journal of Vascular and Endovascular Surgery. - 2021. - Т. 61, № 2. - С. 248-256.
20. Kaplovitch E. et al. Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial // JAMA cardiology. - 2021. - Т. 6, № 1. - С. 21-29.
21. Ambler G. K. et al. Network metaanalysis of the benefit of aspirin with rivaroxaban vs. clopidogrel for patients with stable symptomatic lower extremity arterial disease // European Journal of Vascular and Endovascular Surgery. - 2021. - Т. 62, № 4. - С. 654-655.
22. Nordanstig J. et al. European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication 5 // European Journal of Vascular and Endovascular Surgery. - 2024. - Т. 67, № 1. - С. 9-96.
23. Hess C. N., Huang Z., Patel M. R. et al. Acute Limb Ischemia in Peripheral Artery Disease // Circulation. - 2019. - Т. 140, № 7. - С. 565.
24. Острая ишемия конечностей : национальные рекомендации / Российское общество ангиологов и сосудистых хирургов. - 2024. - URL: https://www.angiolsurgery.org/library/recommendations/2022/ischaemia/recommendation.pdf
25. Wang S. K. et al. Perioperative outcomes are adversely affected by poor pretransfer adherence to acute limb ischemia practice guidelines // Annals of Vascular Surgery. - 2018. - Т. 50. - С. 46-51